# Leveraging innovative technologies in basic and clinical cancer research

> **NIH NIH T32** · STANFORD UNIVERSITY · 2023 · $406,309

## Abstract

PROJECT SUMMARY
This application requests funds to continue the highly successful Cancer Biology T32 training program at the
Stanford University School of Medicine. The current application will present a new vision for this training program,
in which the innovative technologies developed and used at Stanford will become a cornerstone of the cancer
research program, in a proposal entitled “Leveraging innovative technologies in basic and clinical cancer research”.
The goal of this training program is to provide the very best training for its predoctoral trainees so that they become
successful and independent leaders in the field of cancer research. The program accomplishes this goal by
providing each trainee with a broad and comprehensive curriculum, a vast array of educational resources such as
seminars, lectures, conferences and workshops specifically geared toward the biology of cancer, a faculty
comprising 49 exceptional preceptors with extensive experience in cancer research mentoring, and an unparalleled
research environment. The success of the training program is demonstrated by its track record of attracting
outstanding and talented predoctoral candidates to Stanford University and placing graduates of the program in
high-profile competitive cancer research positions in academia, industry, and medicine. During the next 5-year
period, there will be a number of new initiatives. The program will focus on leveraging a variety of cutting-edge
technologies pioneered by T32 faculty at Stanford to better understand cancer development and to help develop
improved cancer diagnostics and therapeutics. The strong technology emphasis of the program is a key strength
that will promote a truly multidisciplinary approach to cancer research, enabling collaborations between individuals
in diverse fields such as systems biology, functional genomics, epigenetics, immuno-oncology, and cancer stem
cell biology. In addition, the research conducted by T32 preceptors has a significant clinical focus, with the goal of
ultimately improving cancer care. Our curriculum, which we have designed to provide trainees with a solid core of
cancer biology coursework while allowing flexibility in electives to match individual needs in areas of specialization
(e.g., computational biology), will now also include technology-oriented coursework. We have also introduced a
clinical course to expose students to the translational side of cancer biology as well as “T32 chats” to teach students
about translational cancer biology and pitfalls associated with various technologies. We are taking various measures
to increase diversity in the program, such as through the Social Justice Working Group. We are promoting career
development by providing leadership opportunities for students, access to teaching opportunities, and career
workshops with alumni to give exposure to different potential career options. To ensure optimal mentors, we will
also have a new rigorous selection process for T32 ...

## Key facts

- **NIH application ID:** 10628305
- **Project number:** 2T32CA009302-46
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** LAURA D ATTARDI
- **Activity code:** T32 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $406,309
- **Award type:** 2
- **Project period:** 1977-09-15 → 2028-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10628305

## Citation

> US National Institutes of Health, RePORTER application 10628305, Leveraging innovative technologies in basic and clinical cancer research (2T32CA009302-46). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10628305. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*